After FDA setback, PTC Therapeutics' DMD drug Translarna faces possible market...

cafead

Administrator
Staff member
  • cafead   Sep 15, 2023 at 12:02: PM
via A “surprised and extremely disappointed” PTC Therapeutics is scrambling to keep its Duchenne muscular dystrophy therapy Translarna on the European market after a detrimental review.

article source